Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study

Abstract Background Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation and concurrent mutations have a poor prognosis. This study aimed to examine anlotinib plus icotinib as a first-line treatment option for advanced NSCLC carrying EGFR mutation with or...

Full description

Bibliographic Details
Main Authors: Linlin Zhang, Liuchun Wang, Jingya Wang, Jinliang Chen, Zhaoting Meng, Zhujun Liu, Xiangli Jiang, Xinyue Wang, Chun Huang, Peng Chen, Yan Liang, Richeng Jiang, Jing Wang, Diansheng Zhong, Yanhong Shang, Yan Zhang, Cuiying Zhang, Dingzhi Huang
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Molecular Cancer
Subjects:
Non-small-cell lung cancer
ErbB receptors
Prognosis
Safety
Anlotinib
Icotinib
Online Access:https://doi.org/10.1186/s12943-023-01823-w

Internet

https://doi.org/10.1186/s12943-023-01823-w

Similar Items